Compare · BBOT vs NVO
BBOT vs NVO
Side-by-side comparison of BridgeBio Oncology Therapeutics Inc. (BBOT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBOT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 324.9x BBOT ($685.7M).
- Over the past year, BBOT is down 19.8% and NVO is down 22.5% - BBOT leads by 2.7 points.
- BBOT has been more active in the news (7 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 9 for BBOT).
- Company
- BridgeBio Oncology Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $8.56+3.32%
- $50.31-2.25%
- Market cap
- $685.7M
- $222.81B
- 1M return
- +11.38%
- +15.47%
- 1Y return
- -19.80%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 7
- 4
- Recent ratings
- 9
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BBOT
- Analyst initiated coverage on BridgeBio Oncology Therapeutics with a new price target
- COO & Principal Financial Ofcr Elmelech Idan covered exercise/tax liability with 343 shares, decreasing direct ownership by 2% to 14,495 units (SEC Form 4) (for withholding tax)
- Principal Accounting Officer Cobo Marc covered exercise/tax liability with 125 shares, decreasing direct ownership by 2% to 5,306 units (SEC Form 4) (withholding tax)
- President and CEO Beltran Pedro covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 44,576 units (SEC Form 4) (for withholding tax)
- Chief Med & Dev Officer Ben Yong covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 44,576 units (SEC Form 4) (tax withholding)
- Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Oncology Therapeutics Inc.
- Director Chen Bihua disposed of 4,528,186 shares and acquired 4,528,186 shares (SEC Form 4)
- SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
- SEC Form 8-K filed by BridgeBio Oncology Therapeutics Inc.
- Oppenheimer resumed coverage on BridgeBio Oncology Therapeutics with a new price target
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S